grant

Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia

Organization UNIVERSITY OF ALABAMA AT BIRMINGHAMLocation BIRMINGHAM, UNITED STATESPosted 15 Dec 2021Deadline 30 Jun 2026
NIHUS FederalResearch GrantFY2025AD dementiaActive Follow-upAffectAgeAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimers DementiaAmentiaAssayAutopsyBioassayBiological AssayBiological MarkersBiopsyBiopsy SampleBiopsy SpecimenBody TissuesBrainBrain Nervous SystemCNS Nervous SystemCadaverCaringCentral Nervous SystemCerebrospinal FluidClinicalClinical TrialsColonColonoscopyCorticodentatonigral degeneration with neuronal achromasiaDegenerative Neurologic DisordersDementiaDementia with Lewy BodiesDepositDepositionDermatologic biopsyDetectionDiagnosisDiagnostic testsDifferential DiagnosisDiseaseDisorderDysfunctionEarly DiagnosisEmergent TechnologiesEmerging TechnologiesEncephalonEnteric Nervous SystemFunctional disorderGoalsHypersensitivity skin testingImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologicsLB dementiaLewy Body DementiaLewy Body Type Senile DementiaLewy dementiaLumbar PunctureMT-bound tauMeasuresMedicalMethodsNAC precursorNasalNasal Passages NoseNervous System Degenerative DiseasesNervous System DiseasesNervous System DisorderNeural Degenerative DiseasesNeural degenerative DisordersNeuraxisNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNeurologic DisordersNeurological DisordersNosePARK1 proteinPARK4 proteinPD with dementiaParkinson Disease dementiaParkinson plus syndromesParkinson's DementiaParkinson's disease with dementiaParkinsonianParkinsonian ConditionParkinsonian DiseasesParkinsonian DisordersParkinsonian SyndromeParkinsonismPatient CarePatient Care DeliveryPatient RecruitmentsPatientsPeripheralPersonsPhysiopathologyPrimary Senile Degenerative DementiaProctosigmoidoscopyProgressive Supranuclear OphthalmoplegiaProgressive Supranuclear PalsyReportingResearch SpecimenRespiratory System, Nose, Nasal PassagesSNCASNCA proteinSalivary GlandsSamplingSensitivity and SpecificitySeverity of illnessSigmoidSigmoid colonSigmoidoscopySkinSkin TestsSpecimenSpinal PunctureSteele-Richardson-Olszewski DiseaseSteele-Richardson-Olszewski SyndromeSubmandibular glandSubmaxillary GlandSymptomsTauopathiesTestingTimeTissuesa-syna-synucleinabnormally aggregated tau proteinactive followupagesalpha synucleinalpha synuclein genealphaSP22asynatypical parkinsonian disorderatypical parkinsonian syndromeatypical parkinsonismbio-markersbiologic markerbiomarkerbiomarker identificationcadavericcadaverscare for patientscare of patientscaring for patientscerebral spinal fluidco-morbidco-morbiditycohortcomorbiditycomparator groupcomparison groupcortical basal degenerationcorticobasal degenerationcutaneous biopsydegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdementia in PDdementia in Parkinson diseasediagnostic approachdiagnostic biomarkerdiagnostic markerdiagnostic strategydiagnostic tooldisease severityearly detectionfilamentous tau inclusionfollow upfollow-upfollowed upfollowuphypersensitivity testidentification of biomarkersidentification of new biomarkersimmunologic skin testimprovedinsoluble aggregatemarker identificationmicrotubule associated protein tau aggregationmicrotubule associated protein tau depositmicrotubule bound taumicrotubule-bound taunecropsyneurodegenerative illnessneurological diseaseneuropathologicneuropathologic tauneuropathologicalneuropathological tauneuropathologynon A-beta component of AD amyloidnon A4 component of amyloid precursorpaired helical filament of tauparticipant enrollmentparticipant recruitmentpathophysiologypatient enrollmentpatient stratificationpostmortemprimary degenerative dementiaprion-likeprotein aggregateprotein aggregationself-aggregate tausenile dementia of the Alzheimer typeskin biopsyspinal fluidstratified patientsynucleinopathytautau PHFtau Proteinstau accumulationtau aggregatetau aggregationtau associated neurodegenerationtau associated neurodegenerative processtau driven neurodegenerationtau factortau fibrillizationtau filamenttau induced degenerationtau induced neurodegenerationtau mediated neurodegenerationtau neurodegenerative diseasetau neurofibrillary tangletau neuropathologytau oligomertau paired helical filamenttau pathologytau pathophysiologytau polymerizationtau proteinopathytau related neurodegenerationtau-induced pathologytau-tau interactiontauopathic neurodegenerative disordertauopathytherapeutic agent developmenttherapeutic developmenttissue biomarkersα synuclein geneα-synα-synucleinτ Proteinsτ aggregation
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Abstract
The overall goal of our project is to validate a diagnostic tool for dementia with Lewy bodies (DLB), and

Parkinson’s disease dementia (PDD), two common neurodegenerative diseases affecting 1.4 million people in

the U.S. Currently, definitive diagnosis of DLB and PDD often requires the postmortem detection of disease-

associated alpha-synuclein (αSynD) aggregates in the brain. Clinically, DLB and PDD can be easily

misdiagnosed with other dementias and parkinsonisms such as Alzheimer’s disease (AD) and tauopathies. An

unmet medical need is to identify biomarkers for early and differential diagnosis of DLB and PDD in more easily

accessible tissues. We have taken advantage of the emerging technology known as the real-time quaking

induced conversion (RT-QuIC) assay to develop a robust platform for ultrasensitive detection of αSynD in

peripheral tissues. In preliminary studies, we are able to detect prion-like seeding activity of αSynD in the skin of

DLB and PD patients with 100% specificity and sensitivity. In addition, we were remarkably successful in

detecting αSynD seeding activity in multiple peripheral tissues including skin, sigmoid colon, and submandibular

glands in autopsied specimens. We hypothesize that RT-QuIC of peripheral αSynD is a highly sensitive and

robust diagnostic biomarker for premortem diagnoses of DLB and PDD. To test this hypothesis, we propose

to pursue the following four Aims: (1) Establish peripheral αSynD as a biomarker for postmortem diagnosis of

DLB and PDD using RT-QuIC assay; (2) Assess skin αSynD as a biomarker for premortem diagnosis of DLB and

PDD; (3) Determine peripheral αSynD and tau as a biomarker for differentiating DLB and PDD from other

dementias and parkinsonisms such as AD and tauopathies; (4) Explore gut αSynD as a biomarker for premortem

diagnosis of DLB and PDD using colon biopsy. Successful implementation of this proposal will establish RT-

QuIC assay utilization for early diagnosis of DLB and PDD using readily available peripheral specimens.

Grant Number: 5R01NS118760-06
NIH Institute/Center: NIH

Principal Investigator: SHU CHEN

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →